source
- Replimune’s Tudriqev immunotherapy receives FDA accelerated approval for advanced melanomaReplimune announced that the FDA granted accelerated approval for its immunotherapy, now branded Tudriqev, in combination with Bristol Myers Squibb’s Opdivo. The decision follows two earlier reject…
- Replimune secures FDA accelerated approval for melanoma therapy after two prior rejectionsReplimune, a biotech based in Massachusetts, has received accelerated approval from the U.S. Food and Drug Administration for its melanoma drug. The approval comes after the therapy was rejected tw…